Category: Corporate NewsBy adminMay 17, 2020 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Disclosure to EGX on BOD minutesNextNext post:EGX disclosure regarding Rameda’s manufacturing of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture RemedsivirRelated PostsEarnings Release One-Pager 4Q24March 10, 2025Earning Release One Pager 3Q24November 14, 2024Rameda Completes Largest Acquisition to DateSeptember 30, 2024Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketSeptember 9, 2024Earning Release One Pager 2Q24August 13, 2024Rameda Announces Price Increase Approvals for All Its Top ProductsAugust 7, 2024
Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketSeptember 9, 2024
